Lymph node dissection, the standard surgical treatment for melanoma, does not increase patient survival rates, according to a study published in The New England Journal of Medicine. Lymph node ...

Iovance Biotherapeutics announced positive five-year results from its Phase 2 C-144-01 clinical trial for Amtagvi® (lifileucel), a T cell therapy for advanced melanoma patients who previously received ...

A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

Cancer is a broad term used to describe the uncontrollable proliferation of mutated cells deleterious to the body. Any tissue in the body can become mutated and drive tumor progression. Unfortunately, ...

Regional anesthesia can improve survival rates in patients with malignant melanoma, the deadliest form of skin cancer, according to a study presented at this year’s American Society of ...

For the first time ever, the five-year survival rate for all cancers combined has reached 70 percent. While it’s a moment to celebrate, doctors warn the fight is far from over. Sean Stevenson ...

Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.

Iovance Biotherapeutics, Inc. announced promising five-year follow-up results from the Phase 2 C-144-01 clinical trial of their T cell therapy Amtagvi® (lifileucel) for advanced melanoma. Published in ...

Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors PURPOSE: Immune complexes (IC) containing the ...